China Regulatory Update: CFDA Wants Your Views By October
This article was originally published in PharmAsia News
Five medical device regulations and four draft regulations released within one month, but what do you think of the China FDA’s regulatory work? Now it’s your turn to have a voice as the regulator is collecting public comments - but hurry as the window is closing soon.
You may also be interested in...
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.
The China bioventure sector is poised to set a record for initial public offerings and fundraising, but one therapeutic area is taking a surprise lead - immunology.